Advances in therapeutic bacterial antisense biotechnology

John P. Hegarty, David Stewart

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Antisense therapeutics are a biotechnological form of antibiotic therapy using chemical analogues of short single-stranded nucleic acid sequences modified to form stable oligomers. These molecules are termed antisense oligonucleotides (ASOs) because their sequence is complementary, via Watson-Crick specific base pairing, to their target messenger RNA (mRNA). ASOs modify gene expression in this sequence-dependent manner by binding to its complementary mRNA and inhibiting its translation into protein through steric blockage and/or through RNase degradation of the ASO/RNA duplex. The widespread use of conventional antibiotics has led to the increasing emergence of multiple drug-resistant pathogenic bacteria. There is an urgent need to develop alternative therapeutic strategies to reduce the morbidity and mortality associated with bacterial infections, and until recently, the use of ASOs as therapeutic agents has been essentially limited to eukaryotic cells, with ASOs as antibacterials having been largely unexplored primarily due to the poor uptake efficiency of antisense molecules by bacteria. There are conceptual advantages to bacterial antisense antibiotic therapies, including a sequence-dependent approach that allows for a rational design to multiple specific molecular targets. This review summarizes the current knowledge of antisense bacterial biotechnology and highlights the recent progress and the current obstacles in their development for therapeutic applications.

Original languageEnglish (US)
Pages (from-to)1055-1065
Number of pages11
JournalApplied Microbiology and Biotechnology
Volume102
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Biotechnology
Antisense Oligonucleotides
Anti-Bacterial Agents
Therapeutics
Bacteria
Antisense RNA
Complementary RNA
Messenger RNA
Protein Biosynthesis
Eukaryotic Cells
Ribonucleases
Bacterial Infections
Base Pairing
Nucleic Acids
Morbidity
Gene Expression
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Hegarty, John P. ; Stewart, David. / Advances in therapeutic bacterial antisense biotechnology. In: Applied Microbiology and Biotechnology. 2018 ; Vol. 102, No. 3. pp. 1055-1065.
@article{61574dde983d4c8da0d6e25b0e545f86,
title = "Advances in therapeutic bacterial antisense biotechnology",
abstract = "Antisense therapeutics are a biotechnological form of antibiotic therapy using chemical analogues of short single-stranded nucleic acid sequences modified to form stable oligomers. These molecules are termed antisense oligonucleotides (ASOs) because their sequence is complementary, via Watson-Crick specific base pairing, to their target messenger RNA (mRNA). ASOs modify gene expression in this sequence-dependent manner by binding to its complementary mRNA and inhibiting its translation into protein through steric blockage and/or through RNase degradation of the ASO/RNA duplex. The widespread use of conventional antibiotics has led to the increasing emergence of multiple drug-resistant pathogenic bacteria. There is an urgent need to develop alternative therapeutic strategies to reduce the morbidity and mortality associated with bacterial infections, and until recently, the use of ASOs as therapeutic agents has been essentially limited to eukaryotic cells, with ASOs as antibacterials having been largely unexplored primarily due to the poor uptake efficiency of antisense molecules by bacteria. There are conceptual advantages to bacterial antisense antibiotic therapies, including a sequence-dependent approach that allows for a rational design to multiple specific molecular targets. This review summarizes the current knowledge of antisense bacterial biotechnology and highlights the recent progress and the current obstacles in their development for therapeutic applications.",
author = "Hegarty, {John P.} and David Stewart",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s00253-017-8671-0",
language = "English (US)",
volume = "102",
pages = "1055--1065",
journal = "Applied Microbiology and Biotechnology",
issn = "0175-7598",
publisher = "Springer Verlag",
number = "3",

}

Advances in therapeutic bacterial antisense biotechnology. / Hegarty, John P.; Stewart, David.

In: Applied Microbiology and Biotechnology, Vol. 102, No. 3, 01.02.2018, p. 1055-1065.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in therapeutic bacterial antisense biotechnology

AU - Hegarty, John P.

AU - Stewart, David

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Antisense therapeutics are a biotechnological form of antibiotic therapy using chemical analogues of short single-stranded nucleic acid sequences modified to form stable oligomers. These molecules are termed antisense oligonucleotides (ASOs) because their sequence is complementary, via Watson-Crick specific base pairing, to their target messenger RNA (mRNA). ASOs modify gene expression in this sequence-dependent manner by binding to its complementary mRNA and inhibiting its translation into protein through steric blockage and/or through RNase degradation of the ASO/RNA duplex. The widespread use of conventional antibiotics has led to the increasing emergence of multiple drug-resistant pathogenic bacteria. There is an urgent need to develop alternative therapeutic strategies to reduce the morbidity and mortality associated with bacterial infections, and until recently, the use of ASOs as therapeutic agents has been essentially limited to eukaryotic cells, with ASOs as antibacterials having been largely unexplored primarily due to the poor uptake efficiency of antisense molecules by bacteria. There are conceptual advantages to bacterial antisense antibiotic therapies, including a sequence-dependent approach that allows for a rational design to multiple specific molecular targets. This review summarizes the current knowledge of antisense bacterial biotechnology and highlights the recent progress and the current obstacles in their development for therapeutic applications.

AB - Antisense therapeutics are a biotechnological form of antibiotic therapy using chemical analogues of short single-stranded nucleic acid sequences modified to form stable oligomers. These molecules are termed antisense oligonucleotides (ASOs) because their sequence is complementary, via Watson-Crick specific base pairing, to their target messenger RNA (mRNA). ASOs modify gene expression in this sequence-dependent manner by binding to its complementary mRNA and inhibiting its translation into protein through steric blockage and/or through RNase degradation of the ASO/RNA duplex. The widespread use of conventional antibiotics has led to the increasing emergence of multiple drug-resistant pathogenic bacteria. There is an urgent need to develop alternative therapeutic strategies to reduce the morbidity and mortality associated with bacterial infections, and until recently, the use of ASOs as therapeutic agents has been essentially limited to eukaryotic cells, with ASOs as antibacterials having been largely unexplored primarily due to the poor uptake efficiency of antisense molecules by bacteria. There are conceptual advantages to bacterial antisense antibiotic therapies, including a sequence-dependent approach that allows for a rational design to multiple specific molecular targets. This review summarizes the current knowledge of antisense bacterial biotechnology and highlights the recent progress and the current obstacles in their development for therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=85037643663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037643663&partnerID=8YFLogxK

U2 - 10.1007/s00253-017-8671-0

DO - 10.1007/s00253-017-8671-0

M3 - Review article

C2 - 29209794

AN - SCOPUS:85037643663

VL - 102

SP - 1055

EP - 1065

JO - Applied Microbiology and Biotechnology

JF - Applied Microbiology and Biotechnology

SN - 0175-7598

IS - 3

ER -